CatalystMarker
← board

CTTH

distress 6/10 · elevated risk
$0.060%today-39% from 52w high
cttpharmaceuticals.com1 employeesTampa, FLDrug Manufacturers - Specialty & Generic
Revenue
pre-revenue
Liquidity
$0M
Runway
0.1 yrs
Shares 1y
+140%

Price & events

-23.6% over 6M
$0.06$0.08$0.10Jan 26Apr 26Jul 26210kdilution: S-1/A shelf_registration (2026-07-13)dilution: S-1/A shelf_registration (2026-06-29)dilution: S-1/A shelf_registration (2026-06-16)dilution: S-1/A shelf_registration (2026-05-29)dilution: S-1/A shelf_registration (2026-04-15)
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
-7.4%
1W
-23.6%
1M
-18.5%
3M
-23.6%
6M
+70.7%
1Y
+40.1%
2Y
+19.8%
5Y
-6.0%
All

Overview

Market Cap
$1.30M
Volume
46.28K
52 Week Range
$0.03 – $0.10
Total Shares
21.35M
Float Shares
29.16M
% Held by Insiders
50.32%
% Held by Institutions
0.00%
RVOL
3.02x
Beta
0.71

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 0

  • No catalyst news yet.

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 21,349,377 · 0 offerings/1y · 0 PIPEs
  • 2026-07-13S-1/Ashelf_registration
  • 2026-06-29S-1/Ashelf_registration
  • 2026-06-16S-1/Ashelf_registration
  • 2026-05-29S-1/Ashelf_registration
  • 2026-04-15S-1/Ashelf_registration
  • 2025-12-30S-1shelf_registration
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors

  • none identified

Recent news

  • none

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.